keyword
MENU ▼
Read by QxMD icon Read
search

hematological stem cell transplantation

keyword
https://www.readbyqxmd.com/read/27910184/clinical-significance-of-pre-transplant-circulating-cd3-cd4-cd161-cell-frequency-on-the-occurrence-of-neutropenic-infections-after-allogeneic-stem-cell-transplantation
#1
Tae Woo Kim, Sung-Eun Lee, Ji-Young Lim, Da-Bin Ryu, Young-Woo Jeon, Jae-Ho Yoon, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Woo-Sung Min, Chang-Ki Min
BACKGROUND: Few studies have been performed to identify factors that are associated with an increased risk of infections during the neutropenic period in patients undergoing allogeneic stem cell transplantation (allo-SCT). The aim of this study was to identify the host immune cells responsible for infections before engraftment. METHODS: A total of 282 patients who underwent allo-SCT were enrolled. Peripheral blood samples were collected before conditioning therapy...
December 2, 2016: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/27905684/the-effect-of-maternal-and-infant-factors-on-cord-blood-yield
#2
REVIEW
Seyed Hadi Mousavi, Saeid Abroun, Morteza Zarrabi, Mona Ahmadipanah
Umbilical cord blood (CB) can be used as an alternative hematopoietic stem cell source for transplantation in hematological malignancy and blood disorders. The success of transplantation is highly related to the levels of total nucleated cell and CD34(+) cell counts. The evaluation of optimal conditions can decrease the rate of graft rejection due to low cell count and increases the quality of CB units (CBUs) in the blood bank and the success rate of engraftment. To this end, we review the maternal and infant parameters affecting the quality and quantity of CBUs...
December 1, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27905258/hla-mismatched-haploidentical-transplantation-using-low-dose-anti-thymocyte-globulin-atg-thymoglobulin
#3
Shinichi Kako, Yu Akahoshi, Naonori Harada, Hirofumi Nakano, Kazuaki Kameda, Tomotaka Ugai, Ryoko Yamasaki, Hidenori Wada, Yuko Ishihara, Koji Kawamura, Kana Sakamoto, Miki Sato, Masahiro Ashizawa, Kiriko Terasako-Saito, Shun-Ichi Kimura, Misato Kikuchi, Hideki Nakasone, Rie Yamazaki, Junya Kanda, Yoshinobu Kanda
Objectives To clarify optimal strategies for human leukocyte antigen (HLA)-mismatched haploidentical hematopoietic stem cell transplantation (HSCT). Methods Twelve patients who underwent HSCT from a haploidentical related donor using low-dose thymoglobulin were analyzed retrospectively. Thymoglobulin was added to conditioning regimens at 2.5 mg/kg/day for 2 days (days -4 and -3). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine and methotrexate. Results The median age of the patients was 33 years...
December 1, 2016: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/27905193/high-pretransplant-hepcidin-levels-are-associated-with-poor-overall-survival-and-delayed-platelet-engraftment-after-allogeneic-hematopoietic-stem-cell-transplantation
#4
Soichiro Sakamoto, Hiroshi Kawabata, Junya Kanda, Tatsuki Uchiyama, Chisaki Mizumoto, Toshiyuki Kitano, Tadakazu Kondo, Masakatsu Hishizawa, Naohisa Tomosugi, Akifumi Takaori-Kondo
Iron overload is considered a risk factor for mortality in patients with hematopoietic malignancies. Hepcidin is a key regulator of systemic iron balance. We previously reported dynamic changes of serum hepcidin-25 levels in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this study, we retrospectively analyzed the association of pretransplant hepcidin-25 levels with overall survival (OS), engraftment, and other clinical outcomes of allo-HSCT in patients with hematologic malignancies...
December 1, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27904738/recent-developments-in-the-management-of-invasive-fungal-infections-in-patients-with-oncohematological-diseases
#5
REVIEW
Markus Ruhnke, Stefan Schwartz
Patients with hematological cancer have a high risk of invasive fungal diseases (IFDs). These infections are mostly life threatening and an early diagnosis and initiation of appropriate antifungal therapy are essential for the clinical outcome. Most commonly, Aspergillus and Candida species are involved. However, other non-Aspergillus molds are increasingly be identified in cases of documented IFDs. Important risk factors are long lasting granulocytopenia with neutrophil counts below 500/μl for more than 10 days or graft-versus-host disease resulting from allogeneic stem-cell transplantation...
December 2016: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/27904061/diagnosis-and-treatment-of-mucormycosis-in-patients-with-hematological-malignancies
#6
Yuki Asano-Mori
The risk of invasive fungal infections (IFIs) is extremely high in patients with hematological malignancies due to the prolonged and profound neutropenia and immunosuppression after chemotherapy and hematopoietic stem cell transplantation. There has been increasing interest in mucormycosis despite its relatively uncommon occurrence, because occasional breakthrough infections have been observed under anti-aspergillus prophylaxis. The aggressive nature of mucormycosis easily leads to high mortality because of delays in diagnosis and incorrect treatment decisions, which are due in part to lack of adjunctive diagnostic tools and having similar clinical and radiological features with aspergillosis...
2016: Medical Mycology Journal
https://www.readbyqxmd.com/read/27903025/-antifungal-medication-new-substances-new-experiences
#7
Dieter Buchheidt, Wolf-Karsten Hofmann
The incidence of life threatening invasive fungal infections in patients with hematological malignancies during intensive chemotherapy or after hematopoetic stem cell transplantation, patients after solid organ transplantation, ICU patients and premature infants is rising. Mortality rates of invasive fungal infections, caused by Aspergillus species or mucormycetes, may reach 100%, in spite of considerable progress in diagnosis, antifungal prophylaxis and therapy. Comprehensive, profound knowledge of specific diagnostic and current treatment algorithms is essential to improve the prognosis of patients suffering from systemic fungal infections; this article encompasses recent developments in the field of antifungal treatment...
November 2016: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27896234/frequency-and-associated-factors-of-amphotericin-b-nephrotoxicity-in-hospitalized-patients-in-hematology-oncology-wards-in-the-southwest-of-iran
#8
Iman Karimzadeh, Marziyeh Heydari, Mani Ramzi, Mohammad Mahdi Sagheb
BACKGROUND: Nephrotoxicity is the most clinically significant adverse reaction of amphotericin B. Different aspects of amphotericin B (AmB) nephrotoxicity have not been studied well in our population. OBJECTIVES: The purpose of this study was to assess the frequency, time onset, and possible associated factors of AmB nephrotoxicity in hospitalized patients in hematology-oncology wards in the southwest of Iran. PATIENTS AND METHODS: A cross-sectional, observational study was performed over a period of 9 months at 2 hematology-oncology and 1 hematopoietic stem cell transplantation wards at Namazi Hospital...
September 2016: Nephro-urology Monthly
https://www.readbyqxmd.com/read/27895644/recent-developments-in-cellular-immunotherapy-for-hsct-associated-complications
#9
REVIEW
Monica Reis, Justyna Ogonek, Marsela Qesari, Nuno M Borges, Lindsay Nicholson, Liane Preußner, Anne Mary Dickinson, Xiao-Nong Wang, Eva M Weissinger, Anne Richter
Allogeneic hematopoietic stem cell transplantation is associated with serious complications, and improvement of the overall clinical outcome of patients with hematological malignancies is necessary. During the last decades, posttransplant donor-derived adoptive cellular immunotherapeutic strategies have been progressively developed for the treatment of graft-versus-host disease (GvHD), infectious complications, and tumor relapses. To date, the common challenge of all these cell-based approaches is their implementation for clinical application...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27893130/effect-of-inpatient-palliative-care-on-quality-of-life-2-weeks-after-hematopoietic-stem-cell-transplantation-a-randomized-clinical-trial
#10
Areej El-Jawahri, Thomas LeBlanc, Harry VanDusen, Lara Traeger, Joseph A Greer, William F Pirl, Vicki A Jackson, Jason Telles, Alison Rhodes, Thomas R Spitzer, Steven McAfee, Yi-Bin A Chen, Stephanie S Lee, Jennifer S Temel
Importance: During hospitalization for hematopoietic stem cell transplantation (HCT), patients receive high-dose chemotherapy before transplantation and experience significant physical and psychological symptoms and poor quality of life (QOL). Objective: To assess the effect of inpatient palliative care on patient- and caregiver-reported outcomes during hospitalization for HCT and 3 months after transplantation. Design, Setting, and Participants: Nonblinded randomized clinical trial among 160 adults with hematologic malignancies undergoing autologous/allogeneic HCT and their caregivers (n = 94)...
November 22, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27888540/higher-dose-of-cd34-peripheral-blood-stem-cells-is-associated-with-better-survival-after-haploidentical-stem-cell-transplantation-in-pediatric-patients
#11
Yao Chen, Lan-Ping Xu, Kai-Yan Liu, Huan Chen, Yu-Hong Chen, Xiao-Hui Zhang, Yu Wang, Feng-Rong Wang, Wei Han, Jing-Zhi Wang, Chen-Hua Yan, Xiao-Jun Huang
Haploidentical stem cell transplantation (SCT) is increasingly used to treat pediatric patients with malignant or non-malignant hematological disorders. The CD34+ dose of bone marrow or peripheral blood stem cells (PBSCs) has been shown to be an important determinant of the transplant outcome in adults under various preparative regimens. However, knowledge of the effect of the CD34+ dose in pediatric haploidentical SCT is limited. We analyzed the data of 348 pediatric patients (aged 2-18 years) with acute or chronic leukemia, myelodysplastic syndrome (MDS), and other hematological disorders that received a transplant between 2002 and 2012...
November 26, 2016: Clinical Transplantation
https://www.readbyqxmd.com/read/27881982/milestones-of-hematopoietic-stem-cell-transplantation-from-first-human-studies-to-current-developments
#12
REVIEW
Mateja Kralj Juric, Sakhila Ghimire, Justyna Ogonek, Eva M Weissinger, Ernst Holler, Jon J van Rood, Machteld Oudshoorn, Anne Dickinson, Hildegard T Greinix
Since the early beginnings, in the 1950s, hematopoietic stem cell transplantation (HSCT) has become an established curative treatment for an increasing number of patients with life-threatening hematological, oncological, hereditary, and immunological diseases. This has become possible due to worldwide efforts of preclinical and clinical research focusing on issues of transplant immunology, reduction of transplant-associated morbidity, and mortality and efficient malignant disease eradication. The latter has been accomplished by potent graft-versus-leukemia (GvL) effector cells contained in the stem cell graft...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27876094/nitric-oxide-has-contrasting-age-dependent-effects-on-the-functionality-of-murine-hematopoietic-stem-cells
#13
Sapana Jalnapurkar, Shweta Singh, Moirangthem Ranjita Devi, Lalita Limaye, Vaijayanti Kale
BACKGROUND: The success of hematopoietic stem cell (HSC) transplantation is dependent on the quality of the donor HSCs. Some sources of HSCs display reduced engraftment efficiency either because of inadequate number (e.g., fetal liver and cord blood), or age-related dysfunction (e.g. in older individuals). Therefore, use of pharmacological compounds to improve functionality of HSCs is a forefront research area in hematology. METHODS: Lineage negative (Lin(-)) cells isolated from murine bone marrow or sort-purified Lin(-)Sca-1(+)c-Kit(+)CD34(-) (LSK-CD34(-)) were treated with a nitric oxide donor, sodium nitroprusside (SNP)...
November 22, 2016: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/27872734/allogeneic-hematopoietic-stem-cell-transplantation-for-adult-patients-with-fanconi-anemia
#14
Hosein Kamranzadeh Fumani, Mohammad Zokaasadi, Amir Kasaeian, Kamran Alimoghaddam, Asadollah Mousavi, Babak Bahar, Mohammad Vaezi, Ardeshir Ghavamzadeh
BACKGROUND AND OBJECTIVES: Fanconi anemia (FA) is a rare genetic disorder caused by an impaired DNA repair mechanism which leads to an increased tendency toward malignancies and progressive bone marrow failure. The only curative management available for hematologic abnormalities in FA patients is hematopoietic stem cell transplantation (HSCT). This study aimed to report the results of HSCT in adult or adolescent FA patients. PATIENTS AND METHODS: Twenty FA patients with ages of 16 or more who underwent HSCT between 2002 and 2015 enrolled in this study...
2016: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/27872731/infectious-complications-after-umbilical-cord-blood-transplantation-from-unrelated-donors
#15
REVIEW
Juan Montoro, José Luis Piñana, Federico Moscardó, Jaime Sanz
Umbilical cord-blood (UCB) is a well-recognized alternative source of stem cells for unrelated donor hematopoietic stem cell transplantation (HSCT). As compared with other stem cell sources from adult donors, it has the advantages of immediate availability of cells, absence of risk to the donor and reduced risk of graft-versus-host disease despite donor-recipient HLA disparity. However, the use of UCB is limited by the delayed post-transplant hematologic recovery due, at least in part, to the reduced number of hematopoietic cells in the graft and the delayed or incomplete immune reconstitution...
2016: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/27864218/second-primary-malignancies-in-multiple-myeloma-an-overview-and-imwg-consensus
#16
REVIEW
P Musto, K C Anderson, M Attal, P G Richardson, A Badros, J Hou, R Comenzo, J Du, B G M Durie, J San Miguel, H Einsele, W M Chen, L Garderet, G Pietrantuono, J Hillengass, R A Kyle, P Moreau, J J Lahuerta, O Landgren, H Ludwig, A Larocca, A Mahindra, M Cavo, A Mazumder, P L McCarthy, A Nouel, S V Rajkumar, A Reiman, E R Serra, O Sezer, E Terpos, I Turesson, S Usmani, B M Weiss, A Palumbo
BACKGROUND: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27861958/blood-transfusion-in-hematologic-intensive-care-unit
#17
Sylvain P Chantepie, Jean-Baptiste Mear, Jean-Jacques Parienti, Agnès Bazin, Khaled Benabed, Stéphane Cheze, Anne-Claire Gac, Hyacinthe Johnson-Ansah, Margaret Macro, Quentin Cabrera, Emilie Reboursiere, Charles Lancesseur, Gandhi Damaj, Oumedaly Reman
BACKGROUND: There is increasing evidence that excessive blood transfusion may be associated with impaired survival or cardiovascular events. One way to reduce the number of red blood cells (RBCs) is to transfuse 1 unit (1RBC) instead of 2 units of RBCs (2RBC). STUDY DESIGN AND METHODS: Patients requiring blood transfusions in hematologic intensive care unit were included in a prospective study using a single RBC unit per transfusion and were compared with an historical cohort who received 2 RBC units per transfusion...
November 11, 2016: Transfusion
https://www.readbyqxmd.com/read/27855694/cd274-promotes-cell-cycle-entry-of-leukemia-initiating-cells-through-jnk-cyclin-d2-signaling
#18
Xia Fang, Chiqi Chen, Fangzhen Xia, Zhuo Yu, Yaping Zhang, Feifei Zhang, Hao Gu, Jiangbo Wan, Xiaocui Zhang, Wei Weng, Cheng Cheng Zhang, Guo-Qiang Chen, Aibing Liang, Li Xie, Junke Zheng
BACKGROUND: CD274 (programmed death ligand 1, also known as B7H1) is expressed in both solid tumors and hematologic malignancies and is of critical importance for the escape of tumor cells from immune surveillance by inhibiting T cell function via its receptor, programmed death 1 (PD-1). Increasing evidence indicates that functional monoclonal antibodies of CD274 may potently enhance the antitumor effect in many cancers. However, the role of CD274 in leukemia-initiating cells (LICs) remains largely unknown...
November 17, 2016: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/27853939/wharton-s-jelly-mesenchymal-stromal-cells-as-a-feeder-layer-for-the-ex-vivo-expansion-of-hematopoietic-stem-and-progenitor-cells-a-review
#19
REVIEW
Melania Lo Iacono, Rita Anzalone, Giampiero La Rocca, Elena Baiamonte, Aurelio Maggio, Santina Acuto
In recent years, umbilical cord blood (UCB) has been widely used as an alternative source to bone marrow (BM) for transplantation of hematopoietic stem and progenitor cells (HSPCs) in a variety of hematological and non-hematological disorders. Nevertheless, the insufficient number of UCB-HSPCs for graft represents a major challenge. HSPCs ex vivo expansion prior to transplantation is a valid strategy to overcome this limit. Several attempts to optimize the expansion conditions have been reported, including the use of mesenchymal stromal cells (MSCs) as feeder layer...
November 16, 2016: Stem Cell Reviews
https://www.readbyqxmd.com/read/27842861/-information-and-consent-forms-for-hematopoietic-stem-cell-transplantation-donors-and-recipients-guidelines-from-the-franchophone-society-of-bone-marrow-transplantation-and-cellular-therapy-sfgm-tc
#20
Bénédicte Bruno, Jean-Baptiste Thibert, Nelly Bancillon, Anna Desbos, Abir Fawaz, Isabelle Fournier, Carole Genty, Dominique Issarni, Sandrine Leveille, Christelle Premel, Alice Polomeni, Myriam Renault, Sylvie Tarillon, Anne Wallart, Ibrahim Yakoub-Agha, Dominique Bordessoule
Within the context of the SFGM-TC's 6th workshop series on the harmonization of clinical practices, our workshop proposes a standardization of the informed consent process for hematopoietic stem cell donors and recipients leading up to an autologous or allogenic transplantation. All informed consent was for bone marrow or peripheral stem cell donors, and mononuclear/lymphocyte donors according to usual procedures. The informed consent for autologous and allogenic related or unrelated adults and pediatric transplantation patients have been included...
November 2016: Bulletin du Cancer
keyword
keyword
89259
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"